Our study has important clinical implications, shedding new light on the concept of repositioning ACE inhibitors and ARBs as a novel class of lung cancer chemopreventive agents without the potential deleterious toxicities found in metabolic disorders. This evidence concerns the gene ACE and metabolic disease.